Research projects

  • A novel role for the interleukin-2 pathway in humans and mouse models of type 1 diabetes
  • Genetic control of intestinal microflora in type 1 diabetes susceptibility
  • Impaired Regulatory T cell function in type 1 diabetes

Researcher biography

Dr. Hamilton-Williams is an immunologist who holds a Career Development Fellowship from the Juvenile Diabetes Research Foundation specializing in the pathogenesis of type 1 diabetes. Her early career focused on understanding how specific genetic defects associated with autoimmune disease disrupt immune tolerance leading to type 1 diabetes. Her work was instrumental to our understanding of how defects in the interleukin-2 pathway are linked to type 1 diabetes. Currently a Senior Research Fellow at the University of Queensland Diamantina Institute, her laboratory focuses on the role of the gut microbiota in type 1 diabetes as well as immunotherapeutic approaches aimed at restoring immune tolerance in type 1 diabetes. The Hamilton-Williams lab is using a cutting-edge stool metaproteomic platform to probe the interactions between the gut microbiota and autoimmunity in type 1 diabetes patients. Her work aims to utilize stool microbiota analysis as a tool for monitoring disease progression and response to immune and microbiota targeting therapies. Her second area of focus is the development of an antigen-specific immunotherapy for treatment or prevention of type 1 diabetes. These studies are now being translated for use in type 1 diabetes patients with a clinical trial planned.

Areas of research